For rheumatoid arthritis (RA) patients, biological disease-modifying antirheumatic drugs (bDMARDs) aiming inflammatory cytokines, such as tumor necrosis factor α (TNF-α) or interleukin 6 (IL-6) via the IL-6 receptor (IL-6R), have extended the treatment choices.
The results from the study showed that Sarilumab monotherapy holds superior efficacy and tolerability over Adalimumab monotherapy especially for that rheumatoid arthritis (RA) patients who are unable to continue MTX treatment
The results of the study showed that the stretching exercises were as useful as the Mefenamic acid in treating dysmenorrhea and effect of exercise on relieving menstrual pain increases over time.
The term dysmenorrhea implies to painful cramps and heavy menstrual flow, experienced by most of the women during their menstrual cycle. Pain results in when the uterine pressure produced by the cramps becomes more than 60 mmHg.
This study showed that Capsaicin 8% patch provides modest and statistically significant improvements in pain relief and sleep quality compared with a placebo patch in patients with painful diabetic peripheral neuropathy (PDPN).
A devastating condition that has shown to affect approximately one-quarter of patients with type 2 diabetes mellitus is PDPN. There is lack of data regarding the optimal management of PDPN which has led to variable clinical control with antidepressants, anticonvulsants, or opioid medications. These medications have side effects and are also discontinued due to significant adverse effects, lengthy dose titration, drug-drug interactions, the need for frequent, repeat administration, and the risk of addiction, abuse, and withdrawal symptoms.
A 800 mg/day pharmaceutical-grade Chondroitin sulphate was found to be better than placebo and similar to celecoxib in alleviating pain and enhancing function in patients with symptomatic knee osteoarthritis (OA) over 6 months.
Osteoarthritis is one of the most common musculoskeletal disorders that significantly impact the quality of life of people suffering from it. It is known to be a chief cause of pain, loss of function and disability, and requires medical intervention. The various treatment approaches used for managing knee OA comprises both pharmacological and non-pharmacological modalities.
Secukinumab offers considerable and sustained improvements in patient-reported disease activity and health-related quality of life (HRQoL) by reducing functional impairment, fatigue, and impact on work productivity in patients with active ankylosing spondylitis (AS).
Ankylosing spondylitis (AS) is a chronic immune-mediated inflammatory disease with worldwide prevalence of about 0.2–1.4%. The advancement of AS may result in structural damage of the spine, worsening of joint function, physical disability, and significant functional impairment, culminating in reduced health related quality of life (HRQoL).
- 1 of 21